 |
Thalidomide |
|---|---|
| Trade Name | |
| Orphan Indication | Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients |
| USA Market Approval | USA |
| USA Designation Date | 1995-05-15 00:00:00 |
| Sponsor | Andrulis Research Corporation;11800 Baltimore Avenue, Suite 113;Beltsville, Maryland, 20705 |
